MicroRNA-145-5p Regulates the Epithelial-Mesenchymal Transition in Nasal Polyps by Targeting Smad3
Clinical and Experimental Otorhinolaryngology · 31.05.2024 · 17 (2) · 122-136
DOI: 10.21053/ceo.2023.00025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Otorhinolaryngology, erschienen am 31.05.2024. Verfasst von Mengyu Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Suzhou Clinical Medical Center of Otorhinolaryngology, Head and Neck Surgery, Suzhou People's Livelihood Science and Technology Project, Suzhou People’s Livelihood Science and Technology Project.
Abstract (Originalsprache)
Objectives
The annual prevalence of chronic rhinosinusitis (CRS) is increasing, and the lack of effective treatments imposes a substantial burden on both patients and society. The formation of nasal polyps in patients with CRS is closely related to tissue remodeling, which is largely driven by the epithelial-mesenchymal transition (EMT). MicroRNA (miRNA) plays a pivotal role in the pathogenesis of numerous diseases through the miRNA-mRNA regulatory network; however, the specific mechanism of the miRNAs involved in the formation of nasal polyps remains unclear.
Methods
The expression of EMT markers and Smad3 were detected using western blots, quantitative real-time polymerase chain reaction, and immunohistochemical and immunofluorescence staining. Differentially expressed genes in nasal polyps and normal tissues were screened through the Gene Expression Omnibus database. To predict the target genes of miR-145-5p, three different miRNA target prediction databases were used. The migratory ability of cells was evaluated using cell migration assay and wound healing assays.Results. miR-145-5p was associated with the EMT process and was significantly downregulated in nasal polyp tissues. In vitro experiments revealed that the downregulation of miR-145-5p promoted EMT. Conversely, increasing miR-145-5p levels reversed the EMT induced by transforming growth factor-β1. Bioinformatics analysis suggested that miR-145-5p targets Smad3. Subsequent experiments confirmed that miR-145-5p inhibits Smad3 expression.
Conclusion
Overall, miR-145-5p is a promising target to inhibit nasal polyp formation, and the findings of this study provide a theoretical basis for nanoparticle-mediated miR-145-5p delivery for the treatment of nasal polyps.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Orthopedics, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Oncology, Affiliated Haian Hospital of Nantong University, Nantong, China.
Förderung
- Suzhou Clinical Medical Center of Otorhinolaryngology, Head and Neck Surgery
- Suzhou People's Livelihood Science and Technology Project
- Suzhou People’s Livelihood Science and Technology Project
Zitieren
APA
Zhang, M., Peng, X., Liang, X., Wang, W., Yang, Y., Xu, F., Lu, X., Geng, D., & Li, M. (2024). MicroRNA-145-5p Regulates the Epithelial-Mesenchymal Transition in Nasal Polyps by Targeting Smad3. Clinical and Experimental Otorhinolaryngology, 17(2), 122-136. https://doi.org/10.21053/ceo.2023.00025
Vancouver
Zhang M, Peng X, Liang X, Wang W, Yang Y, Xu F, et al. MicroRNA-145-5p Regulates the Epithelial-Mesenchymal Transition in Nasal Polyps by Targeting Smad3. Clinical and Experimental Otorhinolaryngology. 2024;17(2):122-136. doi:10.21053/ceo.2023.00025
BibTeX
@article{Zhang2024,
author = {Zhang, Mengyu and Peng, Xiaole and Liang, Xiaolong and Wang, Wentao and Yang, Yuqing and Xu, Fan and Lu, Xiaomin and Geng, Dechun and Li, Manyi},
title = {MicroRNA-145-5p Regulates the Epithelial-Mesenchymal Transition in Nasal Polyps by Targeting Smad3},
journal = {Clinical and Experimental Otorhinolaryngology},
year = {2024},
volume = {17},
number = {2},
pages = {122--136},
doi = {10.21053/ceo.2023.00025}
}
EUVIMED